# US 2018/0024149 A1 · Predictive markers of ibd > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2018/0024149 A1 - Document ID: US20180024149A1 - Status: Published application - Kind: A1 - Application number: 15/544,158 - Filed: 2016-01-22 - Published: 2018-01-25 - Earliest claimed: 2015-01-23 - Assignees: Nestec S.A. - Applicants: Nestec S.A. - Inventors: Eduardo Schiffrin; Viral Brahmbhatt; Francois-Pierre Martin; Ivan Montoliu Roura; Serge Andre Dominique Rezzi; Jalil Benyacoub - Web page: https://patentgrep.com/patent/US20180024149A1 ## CPC - G01N 33/92: involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)} - G01N 33/53: Immunoassay; Biospecific binding assay; Materials therefor - G01N 33/6893: {related to diseases not provided for elsewhere} - G01N 2405/04: Phospholipids, i.e. phosphoglycerides - G01N 2405/08: Sphingolipids - G01N 2800/065: Bowel diseases, e.g. Crohn, ulcerative colitis, IBS - G01N 2800/54: Determining the risk of relapse - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) ## Abstract The invention relates to a method, a system and kit for identifying the sample of a patient having IBD or predicting the relapse of IBD in patients based on the measurement of biomarkers in a sample of the patient. The biomarkers can be lipids or amino acids or a combination thereof. ## Claims ### Claim 1 An ex vivo analytical method of determining whether a subject has inflammatory bowel disease (IBD), comprising: providing an isolated biological sample; measuring the concentration of at least two biomarkers in the sample; wherein the concentration is significantly lower or higher than a reference value for the biomarkers indicates that the subject has inflammatory bowel disease, wherein a first biomarker is a lipid selected from the group consisting of glycerophospholipid, sphingolipid and combinations thereof and at least one further biomarker is an amino acid selected from a group consisting of arginine, glutamine, glycine, histidine, isoleucine, leucine, ornithine, serine, threonine, tryptophane, tyrosine phenylalanine, and valine and combinations thereof. ### Claim 2 (depends on 1) The method of claim 1 wherein the concentration of the biomarkers in the sample significantly lower than a reference value for the biomarkers indicates that the subject has inflammatory bowel disease. ### Claim 3 (depends on 1) The method of claim 1 comprising a phosphatidylcholine selected from the group consisting of monoacylphosphatidylcholine, diacylphosphatidylcholine, and alkylacylphosphatidylcholine. ### Claim 4 (depends on 1) The method of claim 1, wherein at least the concentration of 3 of 5 biomarkers is measured. ### Claim 5 (depends on 1) The method of claim 1, for predicting a relapse of IBD. ### Claim 6 (depends on 1) The method of claim 1, wherein a concentration of the biomarker in the sample of the subject that is significantly lower than a reference value for the biomarker indicates that the subject has increased risk of having an IBD relapse. ### Claim 7 (depends on 1) The method of claim 1, wherein at least one further biomarker is selected from the group of amino acids consisting of arginine, glycine, histidine, serine, tryptophan, and phenylalanine and combinations thereof. ### Claim 8 (depends on 7) The method of claim 7, wherein one further biomarker is arginine and at least one further biomarker is selected from the group of amino acids consisting of glycine, histidine, serine, tryptophan, and phenylalanine and combinations thereof. ### Claim 9 (depends on 7) The method of claim 7, wherein one further biomarker is glycine and at least one further biomarker is selected from the group of amino acids consisting of arginine, histidine, serine, tryptophan, and phenylalanine and combinations thereof. ### Claim 10 (depends on 7) The method of claim 7, wherein one further biomarker is histidine and at least one further biomarker is selected from the group of amino acids consisting of arginine, glycine, serine, tryptophan, and phenylalanine and combinations thereof. ### Claim 11 (depends on 7) The method of claim 7, wherein one further biomarker is serine and at least one further biomarker is selected from the group of amino acids consisting of arginine, glycine, histidine, tryptophan, and phenylalanine and combinations thereof. ### Claim 12 (depends on 7) The method of claim 7, wherein one further biomarker is tryptophan and at least one further biomarker is selected from the group of amino acids consisting of arginine, glycine, histidine, serine, and phenylalanine and combinations thereof. ### Claim 13 (depends on 7) The method of claim 7, wherein one further biomarker is phenylalanine and at least one further biomarker is selected from the group of amino acids consisting of arginine, glycine, histidine, serine, and tryptophan and combinations thereof. ### Claim 14 (depends on 7) The method of claim 7, wherein one further biomarker is selected from the group consisting of the amino acids consisting of arginine, glutamine, isoleucine, serine, and threonine and combinations thereof. ### Claim 15 (depends on 1) The method of claim 1, wherein each biomarker is measured in a separate tissue the sample being selected from the group consisting of whole blood, blood serum, or plasma, tissue of the intestinal wall, tissue of the liver, and mesenteric adipose. ### Claim 16 (depends on 1) The method of claim 1, wherein the patient is selected from the group consisting of a pediatric patient, an adult patient, a patient in a non-acute phase of IBD, and a patient in an acute phase of IBD. ### Claim 17 (depends on 1) The method of claim 1, wherein the concentration of the respective biomarker is lower than the reference value by 10%. ### Claim 18 (depends on 1) Use of the biomarkers according to claim 1 to identify the samples of subjects in need of an IBD intervention. ### Claim 19 A system for determining whether a subject has inflammatory bowel disease, the system comprising a device for measuring the concentration of the biomarkers through a method comprising: providing an isolated biological sample; measuring the concentration of at least two biomarkers in the sample; wherein the concentration is significantly lower or higher than a reference value for the biomarkers indicates that the subject has inflammatory bowel disease, wherein a first biomarker is a lipid selected from the group consisting of glycerophospholipid, sphingolipid and combinations thereof and at least one further biomarker is an amino acid selected from a group consisting of arginine, glutamine, glycine, histidine, isoleucine, leucine, ornithine, serine, threonine, tryptophane, tyrosine phenylalanine, and valine and combinations thereof, the system comprising a computer: the computer stores a data base comprising reference values for the concentrations of the biomarkers; the computer stores a software program having instructions causing the computer to receive and store the measured values of the parameters of the sample of a subject; to compare values of said measured parameters to the reference values stored in the system; indicate the sample as belonging to a subject having inflammatory bowel disease if the measured values differ from the reference values; and output the results of step iii. ### Claim 20 A kit for determining whether a subject has inflammatory bowel disease comprising reagents for measuring the concentration of the biomarkers through a method comprising: providing an isolated biological sample; measuring the concentration of at least two biomarkers in the sample; wherein the concentration is significantly lower or higher than a reference value for the biomarkers indicates that the subject has inflammatory bowel disease, wherein a first biomarker is a lipid selected from the group consisting of glycerophospholipid, sphingolipid and combinations thereof and at least one further biomarker is an amino acid selected from a group consisting of arginine, glutamine, glycine, histidine, isoleucine, leucine, ornithine, serine, threonine, tryptophane, tyrosine phenylalanine, and valine and combinations thereof. ### Claim 21 (depends on 20) The kit of claim 20, wherein the reagents are selected from the group of monoclonal antibodies, polyclonal antibodies, single chain antibodies, and Fc fragments and wherein the reagents are specific for said biomarkers.